Exhibits several functions, including AP-2 adaptor complex binding activity; arrestin family protein binding activity; and signaling receptor binding activity. Involved in several processes, including regulation of ERK1 and ERK2 cascade; regulation of apoptotic process; and regulation of cellular protein metabolic process. Localizes to several cellular components, including basolateral plasma membrane; dendritic spine; and postsynaptic density. Used to study congestive heart failure. Biomarker of colitis. Orthologous to human ARRB1 (arrestin beta 1); PARTICIPATES IN calcium signaling pathway via the calcium-sensing receptor; angiotensin II signaling pathway via AT1 receptor; corticotropin-releasing hormone signaling pathway; INTERACTS WITH 2,3,7,8-Tetrachlorodibenzofuran; 2,4,6-trinitrobenzenesulfonic acid; acetamide.
ARRB1 protein affects the reaction [Nicotine promotes the reaction [RB1 protein binds to RAF1 protein]], ARRB1 protein affects the reaction [Nicotine results in increased phosphorylation of and results in increased activity of SRC protein]
Trinitrobenzenesulfonic Acid results in increased expression of ARRB1 mRNA, Trinitrobenzenesulfonic Acid results in increased expression of ARRB1 protein
[6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with AH 23848] inhibits the reaction [[ARRB1 protein modified form binds to SRC protein] which binds to IL1R1 protein] more ...
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in increased expression of ARRB1 mRNA
[Chelating Agents binds to Copper] which results in decreased expression of ARRB1 mRNA, [NSC 689534 binds to Copper] which results in decreased expression of ARRB1 mRNA
[Chelating Agents binds to Copper] which results in decreased expression of ARRB1 mRNA, [NSC 689534 binds to Copper] which results in decreased expression of ARRB1 mRNA
ARRB1 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]], ARRB1 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]
Dopamine promotes the reaction [DRD2 protein affects the localization of ARRB1 protein], GRK2 protein promotes the reaction [Dopamine promotes the reaction [DRD2 protein affects the localization of ARRB1 protein]]
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in increased expression of ARRB1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in increased expression of ARRB1 mRNA
Mesalamine inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of ARRB1 mRNA], Mesalamine inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of ARRB1 protein]
ARRB1 protein affects the reaction [Nicotine promotes the reaction [RB1 protein binds to RAF1 protein]], ARRB1 protein affects the reaction [Nicotine results in increased phosphorylation of and results in increased activity of SRC protein]
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in increased expression of ARRB1 mRNA
[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in increased expression of ARRB1 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in increased expression of ARRB1 mRNA
[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in increased expression of ARRB1 mRNA
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin